Member Info for Vascular

I can certainly see a much higher share price sometime during this year, BUT for me the crux of it will be what messages are given out during the year regarding a) future requirements, b) proven effectiveness of RFTs, c) possible competition. The market will need to see assurances that the demand will continue, as we expect it too. There is no reason why not, the whole world is our market with a leading product - endorsed by the UK government. A strong positive sentiment from the UK government and others, that LFTs will remain a major player in keeping society open for many years will take the Sp much, much higher.

Can I ask what SP you would give ODX for a conservative £150 million revenue for end of next financial year?

Found it straight away searching Open Orphan Chinese.

"The Company is in early discussions with King & Wood Mallesons, acting on behalf of selected Chinese pharmaceutical and life science clients, to secure funding for the further development of this Coronavirus challenge study. It is intended that the major cost of developing this Coronavirus human challenge model will be primarily funded by new Chinese pharmaceutical partner companies who will get a return on their investment from royalties on the sale of this particular challenge study model."
https://www.investegate.co.uk/open-orphan-plc--orph-/rns/coronavirus-challenge-study-model/202003090700063586F/

I have seen reference in a presentation form around a year ago of ORPH "talking" to a chinse company, i can't remember any more detail but will have a look. Probably, has nothing to do with recent events but may explain CFs "a year ago" comment.

This reads as if its the government leaned equipment only confirmed today that is the key to the ODX expansion to 2 million units per week. Anyone know what this special equivalent is. Its not porridge oats is it?
"As part of the contract, DHSC will loan a number of key pieces of manufacturing equipment. Omega said this would lead to the expansion in production capability at its Alva facility in Clackmannanshire, “to ensure the tests are made available as soon as possible”.
2The group believes that it will have the capacity to produce some two million tests per week by the end of April, when combining the government-loaned equipment with its own manufacturing kit."

https://www.scotsman.com/business/scots-life-sciences-firm-omega-wins-contract-supply-millions-covid-tests-3131160

Give me a go, i can squeeze a few more machines on the roof. lol

probably correct ... with the timing of this sp dip...

The potential for Omega to earn more than £200m revenues
With Omega’s capacity to produce 2 million tests per week and c. 100m tests per annum, finnCap notes Omega could generate beyond £200m should it sell all that is produced as ‘arguably the revenue per test could be higher’ – depending on factors such as if Omega does both the manufacturing and packaging of the test.

Omega expects to be able to produce c.2m lateral flow tests per week by 30 April, implying c.100m tests per annum. This capacity theoretically could generate c.£150-200m of revenues, assuming a price per test similar to that which Omega receives from the UK-RTC for producing (cassetting and pouching) its AbC-19 COVID-19 Rapid test. Arguably, the revenue per test could be higher…

finnCap Omega Diagnostics contract and trading update

safe jurisdiction, massive unlimited demand in the UK, plus world wide sales opportunity's = sell as much as can handle, Government support, government the customer ....going from zero to a 2 million units per week plus in the next six weeks...... should i buy or should i sell?

it will come...just watch this space...once the contract appears with some hard numbers....

ODX has become a good defensive stock this year, if and when the market come of the rails....we have unlimited demand for product, a understanding that without our product, the rest of the economy will not improve, the main customer is the UK government and money for our payments already set aside, and waiting to be released, plus the main customer already bankrupt, so no big surprises lol.

Brilliant news, and one step closer to our goal of 2 million units per week! i would have preferred an RNS specifically for this good news and a second , later for the rest which detracted somewhat from this very important mile stone.

Cheers Moniman

The China-CEEC Summit in Beijing, was held yesterday - Feb 9, 2021.
Many things announced but the main message for Europe is a closer working relationship with Central an Western Europe - which is a significant announcement, to make.

The main announcement concerning any Open Orphan Investor at this particular time is
" Xi: China ready to cooperate with CEE countries on vaccines" ................where CEE means Central and Eastern European Country's.
https://www.prnewswire.co.uk/news-releases/xi-china-ready-to-cooperate-with-cee-countries-on-vaccines-898426254.html

Report of the WHO AG on human challenge studies
9 February 2021

Mentions the UK Challenge Trials and HIVO
https://www.who.int/publications/m/item/report-of-the-who-ag-on-human-challenge-studies

So if the value of the spin off is 100 m say, then would equal around 50% of parent company Orphan = approx 15p . On day of spilt as DIM has no value on OO balance sheets then there will be no negative effect on OO shares following the split. Is that how you understand it Moniman.

Earache you mentioned this earlier . "Re the spin-outs. Apparently CF has said 1 for 1 in specie for all of them and expected to be starting in 4 - 6 weeks time. Valuations have been speculated / assessed (the Small Company report suggests an immediate £200m MCap for DIM).

Am i right in thinking that a 1-1 for DIM with a £200 Mcap would mean each new share allocated would be approx, (maybe a bit higher) than todays share price of 28p for OpenOrphan? It would mean for each OO share, another share of similar value would be issued to an investor.!! - that sound so good, it must be wrong. Can someone correct me and put me right on a spin out for DIM of £200 Mcap. Thanks in advance. Vas

for Omiga Diagnostics to anyone crying that the SP had gone down a few pence.

"
My News
"Three UK manufacturers selected to make rapid Covid tests - (Financial Times via NewsPoints Desk)
(Ref: Financial Times)
February 8th, 2021
Email
Print
The UK government has selected three British companies to make rapid COVID-19 tests, as reported Financial Times.

According to two people briefed on the decision, the Department of Health has chosen Omega Diagnostics, SureScreen and Global Access Diagnostics to produce up to 2 million lateral flow devices (LFDs) per day for the UK.

Baroness Dido Harding, the head of Test and Trace, said that "there is very much an ambition to create a domestic UK manufacturing capacity" for LFDs.

The government has been almost entirely reliant on limited supplies of the tests from the US and China.

According to publicly available contracts, the government has spent at least £1.5 billion on the tests, and of that amount US company Innova received £1 billion in contracts.

The health department said that "we now have the largest diagnostic network in UK history, and our procurement strategy for testing ensures the UK has the supplies needed to support both the existing symptomatic testing and the expanding programme of asymptomatic testing being carried out.".

We are talking this sort of money , and Innova have received a £1 Billion worth of contracts at a time when " The government has been almost entirely reliant on limited supplies of the tests from the US and China."

What size of contracts will follow ? Omega will get as much work as they can handle! The share price will go up and up..
https://www.firstwordmedtech.com/node/1042930?tsid=2

Any mention how the talks with the Chinese went?

Well sort of.

https://londonnewstime.com/five-easter-eggs-left-by-the-government-in-todays-announcement-of-a-quick-inspection-order/63229/